Tsuchimoto Kim R sold $456K of MNPR
Tsuchimoto Kim R sold 4,090 shares of Monopar Therapeutics (MNPR) at an average of $111.39 ($108.83–$113.84, $0.46M total) across 6 trades on 2026-08-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The director's sale reduces insider ownership but is unlikely to move the stock significantly.
Market read
A modest insider sale with limited trading relevance; traders may monitor for any follow‑on activity.
What to watch
Potential upcoming clinical data releases could offset any short‑term sell pressure.
Background
SEC Form 4 filing discloses insider transactions; required for transparency.
Ticker impact
Director Tsuchimoto Kim R sold 4,090 shares for $456K via a 10b5‑1 plan, reducing holdings to 7,396 shares.
Potential short‑term pressure on MNPR, likely limited to a few cents.
Form 4 is a primary disclosure; the sale size is small for a mid‑cap biotech, so impact is expected to be modest.
Market effects
Minimal effect on broader biotech sector; similar insider sales are common.
No regional impact; confined to MNPR shareholders.
Low global relevance.
Counterpoint
The sale could be purely portfolio rebalancing under a 10b5‑1 plan, not a negative signal.
Key entities
- CompanyMonopar Therapeutics
Biotech firm developing therapies for rare diseases.
- IndividualTsuchimoto Kim R
Director of Monopar Therapeutics.
